Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastr...

Descripción completa

Detalles Bibliográficos
Autores principales: Costabel, Ulrich, Bendstrup, Elisabeth, Cottin, Vincent, Dewint, Pieter, Egan, Jim J. J., Ferguson, James, Groves, Richard, Hellström, Per M., Kreuter, Michael, Maher, Toby M., Molina-Molina, Maria, Nordlind, Klas, Sarafidis, Alexandre, Vancheri, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003341/
https://www.ncbi.nlm.nih.gov/pubmed/24639005
http://dx.doi.org/10.1007/s12325-014-0112-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003341/
https://www.ncbi.nlm.nih.gov/pubmed/24639005
http://dx.doi.org/10.1007/s12325-014-0112-1

Ejemplares similares